codonoptim
glycoprotein
express
purif
amino
acid
sequenc
sarscov
glycoprotein
urbani
strain
nation
center
biotechnolog
inform
strain
use
design
codonoptim
version
gene
encod
ectodomain
glycoprotein
aa
describ
elsewher
synthet
gene
clone
mychi
invitrogen
frame
cmyc
human
protooncogen
epitop
tag
enabl
detect
purif
similar
approach
use
synthes
codonoptim
gene
encod
fulllength
glycoprotein
truncat
solubl
glycoprotein
gener
polymeras
chain
reaction
pcr
amplif
desir
fragment
vector
encod
clone
gene
sequenc
confirm
error
accumul
pcr
process
construct
transfect
human
epitheli
kidney
hek
cell
use
lipofectamin
invitrogen
filter
supernat
transfect
cell
mix
nickelnitrilotriacet
acid
ninta
agaros
invitrogen
column
filtrat
protein
elut
use
mmoll
imidazol
done
mous
immun
isol
hybridoma
humab
mice
medarex
transgen
human
immunoglobulin
gene
mous
heavychain
immunoglobulin
gene
inactiv
humab
mice
inject
weekli
mg
use
complet
freund
primari
adjuv
follow
incomplet
freund
total
week
elisa
use
measur
serum
respons
anim
kill
serum
respons
reach
plateau
hybridoma
gener
fusion
splenocyt
partner
cell
ratio
hybridoma
supernat
screen
reactiv
elisa
protein
purifi
use
protein
sepharos
bead
amersham
express
stain
human
mab
construct
encod
entir
codonoptim
sarscov
glycoprotein
transfect
cell
use
lipofectamin
transfect
harvest
h
transfect
incub
variou
concentr
mab
bind
detect
use
secondarylabel
goat
antihuman
igg
flow
cytometri
use
facscan
cellquest
softwar
becton
dickinson
detect
bind
glycoprotein
vero
cell
vero
cell
resuspend
pb
contain
fetal
calf
serum
cmyc
epitopetag
protein
consist
first
aa
sarscov
glycoprotein
concentr
nmoll
reaction
incub
h
room
temperatur
presenc
absenc
vari
concentr
mab
bind
detect
use
anti
cmyc
antibodi
bd
bioscienc
pharmingen
follow
phycoerythrinlabel
goat
antimous
igg
jackson
analyz
mean
flow
cytometri
use
facscan
cellquest
softwar
immunoprecipit
western
blot
construct
encod
solubl
secret
describ
figur
transfect
cell
use
lipofectamin
supernat
harvest
filter
incub
purifi
mab
protein
sepharos
bead
precipit
protein
resolv
sdspage
transfer
imobilon
p
millipor
membranebound
protein
detect
use
antihi
cterm
antibodi
invitrogen
follow
dilut
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
jackson
treatment
enhanc
chemiluminesc
ecl
reagent
amersham
autoradiographi
glycoprotein
fragment
supernat
precipit
ninta
agaros
resolv
sdspage
transfer
imobilon
p
western
blot
membranebound
protein
detect
use
mab
follow
antihuman
igg
hrp
ecl
reagent
autoradiographi
neutralizingantibodi
assay
neutral
activ
mab
measur
use
assay
adapt
work
witt
et
al
cite
offic
intern
de
epizooti
manual
diagnost
test
vaccin
terrestri
anim
vero
cell
seed
cellswel
microtit
plate
assay
day
volum
assay
day
antibodi
dilut
preincub
h
viru
stock
urbani
strain
gener
provid
larri
anderson
center
diseas
control
prevent
atlanta
mixtur
viru
antibodi
dilut
ad
cell
replic
one
addit
set
antibodi
dilut
without
viru
includ
control
detect
toxic
posit
neg
control
rabbit
rabbit
preimmun
serum
respect
includ
assay
viru
stock
back
titrat
assay
ensur
inoculum
presenc
absenc
cytopath
effect
cpe
h
incub
determin
microscopi
neutralizingantibodi
assay
titer
mous
serum
done
microneutr
assay
use
dilut
heatinactiv
serum
serum
sampl
test
presenc
antibodi
neutral
infect
sarscov
vero
cell
monolay
use
well
per
dilut
plate
presenc
viral
cpe
read
day
dilut
serum
complet
prevent
cpe
well
calcul
mean
reed
muench
formula
microscop
visual
cpe
medium
replac
pb
reagent
promega
ad
plate
incub
h
gradat
color
uninfect
infect
control
easili
distinguish
visual
metabol
solubl
color
product
concentr
proport
number
viabl
cell
cultur
absorb
reduc
well
signific
cpe
inactiv
viru
sd
ad
absorb
optic
densiti
measur
nm
read
use
univers
plate
reader
el
biotek
instrument
percent
protect
effect
calcul
follow
observ
maximum
cpe
minimum
cpe
x
maximum
cpe
maximum
cpe
refer
absorb
control
well
viru
mab
minimum
cpe
refer
absorb
control
well
viru
mab
protect
mice
mab
mous
studi
approv
anim
care
use
committe
nation
institut
health
bethesda
md
done
approv
anim
biosafeti
level
facil
experi
done
describ
elsewher
brief
femal
balbc
mice
tacon
hous
cage
mice
per
cage
mice
receiv
mab
serum
intraperiton
ip
inject
mice
bled
next
day
determin
level
neutral
antibodi
achiev
lightli
anesthet
mice
challeng
sarscov
administ
intranas
mice
kill
day
later
lung
nasal
turbin
tissu
homogen
wtvol
suspens
lung
nasal
turbin
respect
leibovitz
medium
invitrogen
complement
lglutamin
gibco
piperacillin
sigma
aldrich
gentamicin
invitrogen
amphotericin
b
qualiti
biolog
final
concentr
mmoll
mgl
mgl
mgl
respectivelyviru
titer
express
per
gram
determin
vero
cell
monolay
plate
lower
limit
detect
lung
nasal
turbin
tissu
respect
biacor
assay
surfac
plasmon
reson
technolog
use
determin
affin
mab
fragment
includ
entir
receptorbind
domain
brief
mab
concentr
captur
surfac
biacor
chip
coat
goat
antihuman
fc
polyclon
antibodi
captur
mab
expos
variou
concentr
solut
flow
chip
associ
dissoci
rate
measur
chang
concentr
biomolecul
interfac
chip
media
associ
kon
x
indic
mole
per
liter
indic
second
dissoci
koff
x
rate
constant
calcul
dissoci
constant
kd
koffkon
x
deriv
statist
logtransform
viru
titer
compar
nonparametr
mannwhitney
test
p
consid
statist
signific
gener
character
sarscovneutr
mab
gener
neutral
human
mab
direct
sarscov
transgen
mice
activ
human
immunoglobulin
gene
humab
mice
immun
solubl
ectodomain
sarscov
glycoprotein
describ
elsewher
hybridoma
produc
antibodi
mab
potent
neutral
activ
purifi
fulli
character
peptid
sequenc
analysi
edman
degrad
lightchain
analysi
elisa
mab
demonstr
fulli
human
antibodi
singl
light
chain
mab
chimer
molecul
human
heavi
chain
murin
light
chain
ensur
mab
select
reactiv
fulllength
membranebound
glycoprotein
synthes
codonoptim
gene
encod
fulllength
sarscov
glycoprotein
express
cell
dosedepend
bind
curv
mab
suggest
similar
avid
maxim
bind
nmoll
figur
mab
bound
lower
maxim
intens
mab
suggest
differ
protein
recognit
flow
cytometrybas
assay
mab
specif
block
bind
aa
vero
cell
wherea
mab
show
block
activ
figur
affin
measur
biacor
assay
obtain
use
solubl
glycoprotein
fragment
immobil
mab
show
affin
constant
kd
nmoll
nmoll
mab
respect
character
vitro
neutral
sarscov
mab
measur
neutral
potenc
mab
adapt
microtit
assay
use
diagnost
laboratori
measur
neutral
antibodi
variou
anim
coronavirus
determin
neutral
activ
includ
colorimetr
readout
metabol
activ
cell
well
visual
observ
level
cpe
microtit
well
mab
provid
maxim
protect
effect
colorimetr
assay
concentr
nmoll
repeat
assay
repres
assay
shown
figur
although
neutral
measur
cell
metabol
clearli
show
protect
effect
mab
microscop
inspect
monolay
show
subtl
differ
suggest
infect
cell
even
presenc
highest
concentr
mab
specif
tini
foci
cpe
observ
nearli
everi
well
high
concentr
mab
contrast
cpe
observ
well
high
concentr
mab
figur
microneutr
assay
use
higherconcentr
viru
inoculum
cytoprotect
effect
mab
indistinguish
colorimetr
assay
although
curv
shift
slightli
toward
higher
mab
concentr
data
shown
higherconcentr
viru
inoculum
small
foci
cpe
seen
presenc
highest
concentr
mab
numer
standardconcentr
viru
inoculum
howev
complet
protect
cpe
observ
highest
concentr
mab
figur
determin
bind
epitop
mab
map
epitop
recogn
mab
synthes
gene
encod
glycoprotein
truncat
carboxi
aminotermin
domain
figur
right
two
distinct
pattern
immunoprecipit
observ
mab
figur
top
left
precipit
fragment
includ
except
demonstr
recognit
epitop
within
aa
mab
figur
middl
left
precipit
fragment
ntermin
fragment
aa
demonstr
recognit
epitop
within
aa
mab
display
ident
recognit
pattern
western
blot
denatur
glycoprotein
fragment
demonstr
linear
epitop
recogn
data
shown
immunoprophylact
efficaci
mab
mous
model
viru
challeng
evalu
protect
efficaci
mab
vivo
use
establish
murin
model
sarscov
infect
model
use
demonstr
protect
neutral
antibodi
develop
mice
previous
challeng
live
sarscov
vaccin
inoculum
includ
express
glycoprotein
mice
given
purifi
mab
ip
inject
day
challeng
sarscov
urbani
strain
kill
day
challeng
nonimmun
sera
uninfect
mice
irrelev
mab
palivizumab
medimmun
specif
rsv
infect
use
control
blood
collect
prior
challeng
serum
neutral
titer
mice
treat
mgkg
mab
determin
neutral
viru
sera
mice
treat
mab
incomplet
lowest
dilut
cpe
note
limit
patchi
similar
pattern
neutral
mab
describ
figur
viru
titer
measur
lung
nasal
turbin
tissu
h
challeng
dose
mgkg
mab
provid
signific
protect
replic
viru
lung
tissu
p
figur
viru
undetect
lung
tissu
mice
treat
mgkg
mab
reduct
viru
load
group
mice
treat
mgkg
either
mab
significantli
lower
titer
viru
nasal
turbin
tissu
upper
respiratori
tract
compar
control
mice
treat
irrelev
mab
p
reduct
viru
replic
less
profound
observ
lung
tissu
figur
suggest
greater
protect
effect
mab
mab
found
judg
differ
reduct
viru
titer
mgkg
howev
number
observ
small
show
signific
differ
mab
describ
characterist
mab
effect
neutral
sarscov
vitro
recogn
distinct
linear
epitop
sarscov
glycoprotein
within
extern
theminim
receptorbind
domain
despit
differ
protein
recognit
mab
protect
mice
model
viru
challeng
mechan
neutral
mab
bound
aa
like
direct
interfer
bind
viru
glycoprotein
receptor
neutral
protect
mice
mab
bound
aa
fail
block
bind
vero
cell
must
involv
differ
mechan
simplest
explan
would
interfer
conform
chang
requir
viruscel
membran
fusion
occur
bind
addit
possibl
mechan
includ
alter
physic
properti
sarscov
eg
aggreg
interfer
asyetunrecogn
coreceptor
immunoprophylact
efficaci
mab
murin
model
defin
signific
reduct
viru
load
lung
nasal
turbin
tissu
larg
inoculum
sarscov
experi
use
ensur
infect
effect
could
best
definedw
emphas
model
allow
conclus
regard
modif
sar
prevent
transmiss
sarscov
nonetheless
reason
hypothesi
effect
could
achiev
given
result
preclin
clinic
test
mab
palivizumab
prevent
rsv
diseas
anim
model
rsv
infect
palivizumab
prevent
infect
significantli
reduc
viru
titer
larg
clinic
trial
establish
modif
diseas
prevent
transmiss
achiev
treat
infant
risk
rsv
infect
diseas
palivizumab
review
protect
mice
mab
show
dose
depend
reduct
sarscov
lung
tissu
even
lowest
dose
mgkg
palivizumab
prevent
measur
rsv
infect
provid
benchmark
gaug
feasibl
achiev
effect
dose
sarscovneutr
mab
human
dose
mgkg
palivizumab
provid
effect
prophylaxi
rsv
infect
human
result
anim
studi
suggest
mab
neutral
sarscov
could
use
dose
level
suffici
significantli
reduc
viru
titer
human
demonstr
effect
protect
mab
sarscov
challeng
murin
model
extens
studi
includ
addit
anim
model
demonstr
patholog
import
futur
nonhuman
primat
studi
also
examin
therapeut
efficaci
mab
infect
establish
earli
administr
neutral
mab
might
therapeut
effect
sinc
peak
viru
replic
infect
human
occur
day
onset
symptom
prior
appear
substanti
neutralizingantibodi
titer
given
lag
symptom
onset
maximum
viru
concentr
lung
may
opportun
identifi
treat
individu
neutral
mab
select
human
mab
target
receptorbind
domain
glycoprotein
initi
clinic
studi
safeti
pharmacokinet
glycoprotein
epitop
recogn
mab
demonstr
sequenc
variabl
epidemiolog
studi
therefor
may
stabl
target
neutral
vivo
use
antibodi
prevent
varieti
viral
infect
prove
success
strategi
rapid
develop
safeti
record
human
mab
suggest
primari
role
modal
respons
sar
futur
emerg
infecti
diseas
